X4 Pharmaceuticals, Inc.
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $195.1M | $216.9M | $217.0M | $69.6M | $39.2M | $40.3M | $55.7M | $97.4M |
| Accounts Receivable | $2.0M | $1.1M | $573.0K | $891.0K | $1.1M | $509.0K | $1.1M | $0 |
| Inventory | — | — | — | — | — | — | $2.8M | — |
| Total Current Assets | $218.9M | $242.0M | $261.6M | $132.8M | $72.9M | $95.7M | $112.2M | $143.0M |
| Property, Plant & Equipment | $111.0K | $146.0K | $182.0K | $218.0K | $254.0K | $487.0K | $776.0K | $820.0K |
| Goodwill | $17.4M | $17.4M | $17.4M | $17.4M | $17.4M | $17.4M | $17.4M | $17.4M |
| Intangible Assets (Excl. Goodwill) | $13.1M | $9.1M | $9.3M | $9.4M | $9.6M | $9.8M | $10.0M | $10.2M |
| Total Assets | $253.1M | $270.3M | $290.5M | $163.6M | $105.2M | $130.0M | $146.4M | $178.2M |
| Liabilities | ||||||||
| Accounts Payable | $3.9M | $5.1M | $5.7M | $5.1M | $7.7M | $11.1M | $8.6M | $8.6M |
| Total Current Liabilities | $19.4M | $23.8M | $25.8M | $23.5M | $22.9M | $25.9M | $32.9M | $29.3M |
| Long-Term Debt | $75.0M | $75.0M | $75.0M | $75.0M | $75.0M | $75.0M | $75.0M | $75.0M |
| Total Liabilities | $97.6M | $101.8M | $104.2M | $101.9M | $101.2M | $107.1M | $124.3M | $118.5M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-631.0M | $-614.8M | $-594.6M | $-570.6M | $-540.8M | $-515.1M | $-515.4M | $-475.5M |
| Total Stockholders' Equity | $155.5M | $168.5M | $186.3M | $61.6M | $4.0M | $22.9M | $22.1M | $59.6M |